+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Enzalutamide Soft Capsules Market - Global Forecast 2026-2032- Product Image
Enzalutamide Soft Capsules Market - Global Forecast 2026-2032- Product Image
Sale

Enzalutamide Soft Capsules Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6125986
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Enzalutamide Soft Capsules Market is projected to reach USD 2.98 Billion in 2026. It is expected to continue growing at a CAGR of 10.78%, reaching USD 5.57 Billion by 2032.

Enzalutamide Soft Capsules: Executive Summary

Enzalutamide soft capsules are an oral androgen-receptor signaling inhibitor used in the management of specified prostate cancer settings, including nonmetastatic castration-resistant and metastatic disease, subject to local approvals and prescribing guidance. The market is shaped by oncology treatment protocols, regulatory labeling, oral medicine access, diagnostic capacity, reimbursement, and patient monitoring requirements. This summary focuses on structural developments and strategic implications without presenting market estimates, shares, or forecasts.

Treatment Pathways Are Becoming More Integrated and Evidence-Driven

The landscape is shifting toward earlier identification of treatment-resistant disease, more systematic use of prostate-specific antigen and imaging assessments, and sequencing decisions that reflect prior androgen-deprivation therapy, chemotherapy exposure, disease burden, comorbidities, and patient preferences. Oral administration can support outpatient treatment, but it also increases the importance of adherence support, medication reconciliation, interaction screening, and timely management of fatigue, hypertension, falls, cognitive effects, and other clinically relevant risks.

Access conditions are also transforming. Health systems increasingly evaluate medicines through comparative clinical evidence, budget-impact controls, specialty-pharmacy pathways, and value-based prescribing. Regulatory harmonization, real-world evidence, decentralized care, and digital follow-up are likely to influence how treatment is initiated, monitored, and continued across different healthcare environments.

Artificial Intelligence Can Strengthen Selection, Monitoring, and Evidence Generation

Artificial intelligence can help clinicians and health systems organize longitudinal records, identify treatment patterns, support imaging and pathology workflows, and flag potential medication interactions or adherence risks. Predictive tools may also assist with patient prioritization and symptom surveillance, although their outputs require clinical validation, transparent documentation, and safeguards against bias across demographic and healthcare-access groups.

For manufacturers and providers, AI can improve pharmacovigilance signal detection, trial recruitment, protocol feasibility assessment, and analysis of real-world treatment persistence. These applications do not replace oncologist judgment. They require robust governance covering data quality, privacy, cybersecurity, explainability, regulatory compliance, and human oversight, particularly when algorithms influence treatment sequencing or risk assessment.

Regional Insights: Access, Diagnostics, and Reimbursement Define Adoption Conditions

North America combines advanced oncology infrastructure with extensive specialty prescribing and monitoring capabilities, while payer authorization, affordability, and care fragmentation remain important access considerations. Europe places strong emphasis on health-technology assessment, national or regional reimbursement decisions, guideline alignment, and coordinated cancer care. Asia-Pacific presents substantial variation in diagnostic availability, regulatory pathways, reimbursement, and urban-rural access; mature systems can support sophisticated monitoring, while other settings may prioritize essential oncology capacity and affordability.

Latin America is influenced by public-sector procurement, private insurance coverage, diagnostic inequality, and uneven specialist distribution. The Middle East shows variation between highly resourced national systems and settings where referral networks and medicine availability are more constrained; centralized purchasing and specialist centers can be influential. Africa faces pronounced differences in cancer-diagnosis capacity, treatment financing, specialist access, and supply reliability, making partnerships that strengthen diagnosis, referral, and continuity of care especially relevant.

Group Insights: Policy Alignment and Healthcare Coordination Matter

ASEAN markets require approaches that account for differing regulatory systems, reimbursement structures, specialist capacity, and medicine-distribution networks; regional cooperation can support regulatory dialogue and supply resilience. BRICS countries span highly diverse public and private healthcare models, so access strategies need to reflect domestic production policies, procurement practices, affordability objectives, and uneven oncology infrastructure. The European Union benefits from shared scientific and regulatory frameworks, but reimbursement and treatment implementation remain substantially national or regional.

G7 members generally offer strong clinical research, diagnostic capabilities, and specialist care, while still facing cost-containment, aging-population, and workforce pressures. GCC systems often combine centralized health planning with high investment in tertiary care, though access pathways and procurement practices differ by country. NATO membership is not a healthcare-market homogeneity indicator; relevant considerations include national regulatory autonomy, public-health preparedness, supply-chain resilience, and the varying organization of cancer services across member states.

Country Insights: National Regulation and Care Delivery Shape Use

Australia, Canada, the United Kingdom, and the United States have mature oncology systems, but access is mediated by national or provincial/state reimbursement, formulary review, specialist prescribing, and patient-support infrastructure. France, Germany, Italy, and Spain operate within European regulatory structures while applying distinct assessment, pricing, procurement, and regional-care arrangements. These countries can benefit from evidence packages that address comparative outcomes, quality of life, treatment persistence, and healthcare-resource use.

China and India combine expanding oncology capacity with substantial regional variation in affordability, diagnostic access, hospital concentration, and public-private care. Japan and South Korea have advanced healthcare and specialist networks, with local regulatory, pricing, and clinical-practice requirements shaping uptake. Brazil and Mexico reflect mixed public and private systems, where procurement, insurance coverage, specialist availability, and regional disparities influence continuity of oral cancer treatment. Russia’s treatment environment is shaped by national regulation, public procurement, local supply conditions, and access differences across regions. Across all listed countries, local labeling, clinical guidelines, pharmacovigilance obligations, and reimbursement status must be verified before commercial or clinical decisions are made.

Action Priorities for Leaders: Improve Evidence, Access, and Treatment Continuity

Industry leaders should align clinical-development and access strategies with clearly defined disease settings, comparator expectations, patient-reported outcomes, and local evidence requirements. They should strengthen adherence and safety programs through pharmacist engagement, interaction screening, symptom education, remote follow-up, and rapid escalation pathways. Partnerships with oncology centers, payers, patient organizations, and diagnostic networks can help address referral delays and uneven access without compromising appropriate-use standards.

Operationally, leaders should diversify qualified supply routes, monitor quality and continuity risks, and maintain country-specific regulatory and reimbursement intelligence. AI initiatives should begin with high-value, auditable use cases and include clinical validation, bias testing, cybersecurity controls, and explicit accountability. Decisions should be grounded in verified local evidence rather than assumptions based on regional or group membership.

Research Methodology: Structured Review of Clinical, Regulatory, and Access Evidence

This executive summary uses a structured, evidence-led approach centered on enzalutamide soft capsules. The assessment framework considers approved disease settings, treatment guidelines, safety and monitoring requirements, diagnostic pathways, reimbursement and procurement conditions, healthcare infrastructure, and regional variation. Geographic coverage was organized across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, with additional review through the specified country and group lenses.

Interpretation should be validated against current national product information, regulatory decisions, clinical guidelines, health-technology assessments, payer policies, peer-reviewed studies, pharmacovigilance communications, and credible public-health datasets. Because policies, labels, prices, and supply conditions change, country-level conclusions require date-stamped verification before use. No market estimates, market shares, forecasts, or company-specific claims are included.

Conclusion: Disciplined, Evidence-Based Execution Will Differentiate Access

The enzalutamide soft-capsule landscape is defined by clinically specialized use, evolving prostate-cancer treatment pathways, oral-therapy management demands, and major differences in diagnosis, reimbursement, and oncology capacity. The strongest strategies will connect regulatory compliance and comparative evidence with practical support for adherence, safety monitoring, equitable referral, and continuity of supply.

Regional, group, and country conditions should be treated as distinct operating environments rather than interchangeable categories. Leaders that combine locally verified access intelligence, resilient delivery models, responsible AI governance, and patient-centered care coordination will be better positioned to support appropriate treatment use while responding to changing clinical and health-system expectations.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Enzalutamide Soft Capsules Market, by Dosage Strength
7.1. Introduction
7.2. 120 Mg
7.3. 40 Mg
7.4. 80 Mg
8. Enzalutamide Soft Capsules Market, by Purchase Type
8.1. Introduction
8.2. New Prescription
8.3. Refill
9. Enzalutamide Soft Capsules Market, by Indication
9.1. Introduction
9.2. Metastatic Castration-Resistant Prostate Cancer
9.3. Metastatic Hormone-Sensitive Prostate Cancer
9.4. Non-Metastatic Castration-Resistant Prostate Cancer
10. Enzalutamide Soft Capsules Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Enzalutamide Soft Capsules Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.3.1. Private Hospital
11.3.2. Public Hospital
11.4. Specialty Centers
12. Enzalutamide Soft Capsules Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Enzalutamide Soft Capsules Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Enzalutamide Soft Capsules Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Healthcare Private Limited
16.2. Adley Formulations Private Limited
16.3. Alizyme Healthcare Limited
16.4. Aprazer Healthcare Private Limited
16.5. Astellas Pharma Inc.
16.6. BDR Pharmaceuticals International Private Limited
16.7. Cipla Limited
16.8. Dr. Reddy’s Laboratories Limited
16.9. Glenmark Pharmaceuticals Limited
16.10. Halsted Pharma Private Limited
16.11. Hetero Healthcare Limited
16.12. Intas Pharmaceuticals Limited
16.13. K. K. Pharma Solutions Private Limited
16.14. Medisus Pharma Private Limited
16.15. Pfizer Inc.
16.16. RPG Life Sciences Limited
16.17. Rutika Lifescience Private Limited
16.18. Samarth Life Sciences Private Limited
16.19. Sun Pharmaceutical Industries Limited
16.20. Zydus Lifesciences Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Enzalutamide Soft Capsules Market, Years Considered for the Study
FIGURE 2. Global Enzalutamide Soft Capsules Market, Research Design
FIGURE 3. Global Enzalutamide Soft Capsules Market, Research Framework
FIGURE 4. Global Enzalutamide Soft Capsules Market, Data Triangulation
FIGURE 5. Global Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 7. Global Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Enzalutamide Soft Capsules Market Size, by Purchase Type, 2025 vs 2032 (%)
FIGURE 9. Global Enzalutamide Soft Capsules Market Size, by Purchase Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Enzalutamide Soft Capsules Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Enzalutamide Soft Capsules Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Enzalutamide Soft Capsules Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Enzalutamide Soft Capsules Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Enzalutamide Soft Capsules Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Enzalutamide Soft Capsules Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Enzalutamide Soft Capsules Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Enzalutamide Soft Capsules Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Enzalutamide Soft Capsules Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Enzalutamide Soft Capsules Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Enzalutamide Soft Capsules Market Segmentation & Coverage
TABLE 2. Global Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 3. Global Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 4. Global 120 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global 120 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global 120 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global 40 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global 40 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global 40 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global 80 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global 80 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global 80 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 14. Global New Prescription Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global New Prescription Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global New Prescription Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Refill Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Refill Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Refill Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 21. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Metastatic Castration-Resistant Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Metastatic Hormone-Sensitive Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Metastatic Hormone-Sensitive Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Metastatic Hormone-Sensitive Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Non-Metastatic Castration-Resistant Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Non-Metastatic Castration-Resistant Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Non-Metastatic Castration-Resistant Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 31. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 38. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Private Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Private Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Private Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Public Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Public Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Public Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Specialty Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Specialty Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Specialty Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Enzalutamide Soft Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Enzalutamide Soft Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 61. North America Enzalutamide Soft Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. North America Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 63. North America Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 64. North America Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 65. North America Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 66. North America Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 67. North America Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 68. Latin America Enzalutamide Soft Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Latin America Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 70. Latin America Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 71. Latin America Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 72. Latin America Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 73. Latin America Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. Latin America Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 75. Europe Enzalutamide Soft Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Europe Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 77. Europe Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 78. Europe Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 79. Europe Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. Europe Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Europe Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 82. Middle East Enzalutamide Soft Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Middle East Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 84. Middle East Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 85. Middle East Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 86. Middle East Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 87. Middle East Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 88. Middle East Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 89. Africa Enzalutamide Soft Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Africa Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 91. Africa Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 92. Africa Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 93. Africa Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 94. Africa Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. Africa Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 96. Global Enzalutamide Soft Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. ASEAN Enzalutamide Soft Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. ASEAN Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 99. ASEAN Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 100. ASEAN Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 101. ASEAN Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. ASEAN Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. ASEAN Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 104. GCC Enzalutamide Soft Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. GCC Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 106. GCC Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 107. GCC Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 108. GCC Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. GCC Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. GCC Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 111. European Union Enzalutamide Soft Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. European Union Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 113. European Union Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 114. European Union Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 115. European Union Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 116. European Union Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. European Union Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 118. BRICS Enzalutamide Soft Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. BRICS Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 120. BRICS Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 121. BRICS Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. BRICS Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. BRICS Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. BRICS Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 125. G7 Enzalutamide Soft Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. G7 Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 127. G7 Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 128. G7 Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 129. G7 Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 130. G7 Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. G7 Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 132. NATO Enzalutamide Soft Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. NATO Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 134. NATO Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 135. NATO Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 136. NATO Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. NATO Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. NATO Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 139. Global Enzalutamide Soft Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. United States Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 141. United States Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 142. United States Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 143. United States Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 144. United States Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. United States Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. United States Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 147. Canada Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 148. Canada Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 149. Canada Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 150. Canada Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 151. Canada Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 152. Canada Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. Canada Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 154. Mexico Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 155. Mexico Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 156. Mexico Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 157. Mexico Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. Mexico Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. Mexico Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Mexico Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 161. Brazil Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 162. Brazil Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 163. Brazil Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 164. Brazil Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 165. Brazil Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. Brazil Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Brazil Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 168. United Kingdom Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 169. United Kingdom Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 170. United Kingdom Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 171. United Kingdom Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 172. United Kingdom Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 173. United Kingdom Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. United Kingdom Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 175. Germany Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 176. Germany Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 177. Germany Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 178. Germany Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. Germany Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. Germany Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Germany Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 182. France Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 183. France Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 184. France Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 185. France Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 186. France Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 187. France Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. France Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 189. Russia Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 190. Russia Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 191. Russia Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 192. Russia Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 193. Russia Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. Russia Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. Russia Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 196. Italy Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 197. Italy Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 198. Italy Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 199. Italy Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 200. Italy Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 201. Italy Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. Italy Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 203. Spain Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 204. Spain Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 205. Spain Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 206. Spain Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 207. Spain Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. Spain Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. Spain Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 210. China Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 211. China Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 212. China Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 213. China Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 214. China Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. China Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. China Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 217. India Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 218. India Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 219. India Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 220. India Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 221. India Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 222. India Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. India Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 224. Japan Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 225. Japan Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 226. Japan Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 227. Japan Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 228. Japan Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 229. Japan Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. Japan Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 231. Australia Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 232. Australia Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 233. Australia Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 234. Australia Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 235. Australia Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. Australia Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. Australia Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 238. South Korea Enzalutamide Soft Capsules Market Size, 2017-2032 (USD Million)
TABLE 239. South Korea Enzalutamide Soft Capsules Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 240. South Korea Enzalutamide Soft Capsules Market Size, by Purchase Type, 2017-2032 (USD Million)
TABLE 241. South Korea Enzalutamide Soft Capsules Market Size, by Indication, 2017-2032 (USD Million)
TABLE 242. South Korea Enzalutamide Soft Capsules Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 243. South Korea Enzalutamide Soft Capsules Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. South Korea Enzalutamide Soft Capsules Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 245. Global Enzalutamide Soft Capsules Market Share, by Key Player, 2025
TABLE 246. Global Enzalutamide Soft Capsules Market, Key Experts

Companies Mentioned

  • Abbott Healthcare Private Limited
  • Adley Formulations Private Limited
  • Alizyme Healthcare Limited
  • Aprazer Healthcare Private Limited
  • Astellas Pharma Inc.
  • BDR Pharmaceuticals International Private Limited
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • Glenmark Pharmaceuticals Limited
  • Halsted Pharma Private Limited
  • Hetero Healthcare Limited
  • Intas Pharmaceuticals Limited
  • K. K. Pharma Solutions Private Limited
  • Medisus Pharma Private Limited
  • Pfizer Inc.
  • RPG Life Sciences Limited
  • Rutika Lifescience Private Limited
  • Samarth Life Sciences Private Limited
  • Sun Pharmaceutical Industries Limited
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Enzalutamide Drugs Market - Global Forecast 2026-2032 - Product Image

Enzalutamide Drugs Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Enzalutamide Tablets Market - Global Forecast 2026-2032 - Product Image

Enzalutamide Tablets Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Non-Metastatic Prostate Cancer (NmPC) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Non-Metastatic Prostate Cancer (NmPC) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 230 Pages
  • Global
From
Metastatic Prostate Cancer - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Metastatic Prostate Cancer - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 432 Pages
  • Global
From
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035 - Product Image

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035

  • Report
  • 90 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.